This Month in Psychopharmacology

THIS MONTH IN
PSYCHOPHARMACOLOGY

Veterans Administration Releases Suicide Report
October 12, 2018

With the newly released VA National Suicide Data report, the US Department of Veterans Affairs provides data as to the demographics and suicide rates among Veterans and non-Veteran adults spanning from 2005 to 2016 and...

Continue reading (Members only)

Two New Medications Approved for Migraine Prevention
October 9, 2018

The US Food and Drug Administration (FDA) has approved two anti-calcitonin gene-related peptide (CGRP) treatments for migraines...

Continue reading (Members only)

DEA Reschedules the Cannabidiol Drug Epidiolex
October 6, 2018

Epidiolex, the newly approved medication by the Food & Drug Administration, is being placed in schedule V of the Controlled Substances Act...

Continue reading (Members only)

TMS for Stimulant Withdrawal?
October 4, 2018

A recent randomized control study examined whether application of repetitive transcranial magnetic stimulation (rTMS) to the left DLPFC could modulate withdrawal symptoms from methamphetamine...

Continue reading (Members only)

Increased Risk of Basal Ganglia Disorders in Patients with a History of ADHD?
October 1, 2018

A recent meta-analysis examined whether attention deficit hyperactivity disorder (ADHD), or treatments for the disorder alter the risk of diseases associated with the basal ganglia and cerebellum, including Parkinson’s disease...

Continue reading (Members only)

CDC Releases Recommendations on Diagnosis and Management of TBI in Children
September 28, 2018

The Centers for Disease Control and Prevention (CDC) National Center for Injury Prevention and Control Board of Scientific Counselors, a federal advisory committee, recently established the Pediatric Mild Traumatic Brain Injury Guideline Workgroup...

Continue reading (Members only)

Suicide Prevention
September 26, 2018

September is National Suicide Prevention Awareness Month. NEI had the privilege of interviewing Dr. Christine Moutier, Chief Medical Officer at the American Foundation for Suicide Prevention (AFSP), for the latest NEI Podcast episode....

FDA Finds No Unexpected Safety Risk With Pimavanserin
September 24, 2018

The Food and Drug Administration (FDA) recently completed an extensive review of all postmarking reports of serious adverse events (SAEs) and deaths linked to the use of Nuplazid (pimavanserin)...

Longitudinal Changes in Cognition in Individuals With Ultra-High Risk for Psychosis
September 20, 2018

Cognitive deficits are a core feature of schizophrenia and may be present even before the onset of psychosis. In this 2-year study, researchers investigated baseline measures of cognitive functioning as well as changes in...

Continue reading (Members only)

US Trends in Pediatric ADHD Diagnosis
September 17, 2018

In this large epidemiological survey involving data from 186,457 children and adolescents (age 4-17 years) in the United States, the authors found that the prevalence of attention deficit-hyperactivity disorder has...

Continue reading (Members only)

Top of Page